Bruker has acquired InVivo Biotech Services (Hennigsdorf, Germany), the companies announced Wednesday. The finances of the deal were not disclosed.
Bruker hopes to expand its microbiology assay with this acquisition. Bruker currently has an assay for fast identification of bacteria from positive blood cultures, the MALDI Biotyper, and hopes to expand it using InVivo Biotech’s expertise in monoclonal antibodies.
With $5 million in revenue in 2016, InVivo Biotech offers monoclonal antibodies and recombinant proteins for CMO customers and serves major research institutes, biopharmaceutical and diagnostics companies. It also has a wide selection of bacterial, insect and mammalian protein expression systems for different types of applications.
InVivo Biotech has been in the mammalian cell culture and protein production business for 18 years and is ISO 9001 certified CMO. It offers the production of purified antibodies in various quantities, ranging from milligrams to grams, and uses the subclasses of IgGs, IgMs and IgEs. The antibodies from the subclasses come from 3,000 different hybridoma clones that produce human, rat and mouse monoclonals. InVivo Biotech produces 500 mg of antibody per liter of culture in a day from a serum-free cultivation.
Bruker
bruker.com
[Want to stay more on top of MDO content? Subscribe to our weekly e-newsletter.]
